ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 632,71
0,00%
Dow Jones
40 211,72
0,53%
DAX
18 600,18
0,00%
Brent Oil
83,725
-0,73%
Bitcoin
63 415,48
-2,21%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
09/04/201414h00PR Newswire (US)Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfi...NASDAQ:PTLAPortola Pharmaceuticals Inc
04/04/201412h38Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
04/04/201412h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
02/04/201419h44Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
28/03/201400h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
27/03/201423h59Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
27/03/201413h00GlobeNewswire Inc.Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agen...NASDAQ:PTLAPortola Pharmaceuticals Inc
19/03/201413h00GlobeNewswire Inc.Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agen...NASDAQ:PTLAPortola Pharmaceuticals Inc
18/03/201413h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints John H. Johnson to Board of DirectorsNASDAQ:PTLAPortola Pharmaceuticals Inc
05/03/201414h32PR Newswire (US)Quarterly and Annual Financial Results Release, Executive Appointments, Upcoming Conferences, and Promotion Announcements - A...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/03/201416h17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
27/02/201422h01GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
24/02/201414h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
24/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
20/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, ...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201415h37Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201421h04Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PTLAPortola Pharmaceuticals Inc
03/02/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet ...NASDAQ:PTLAPortola Pharmaceuticals Inc
13/01/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexane...NASDAQ:PTLAPortola Pharmaceuticals Inc
06/01/201414h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 13, 2014NASDAQ:PTLAPortola Pharmaceuticals Inc
09/12/201317h00GlobeNewswire Inc.Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Ant...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/12/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Socie...NASDAQ:PTLAPortola Pharmaceuticals Inc
25/11/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Fac...NASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest EliminationsNASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: -2-NASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest PurchasesNASDAQ:PTLAPortola Pharmaceuticals Inc
15/11/201314h12Dow Jones NewsFidelity Management & Research Co. 3Q 13F: Largest SalesNASDAQ:PTLAPortola Pharmaceuticals Inc
11/11/201314h00GlobeNewswire Inc.Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*)NASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201323h24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
05/11/201322h00GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

NASDAQ
GOOGL
Alphabet
USI
USTECH100
US Tech 100
COIN
ETHUSD
Ethereum
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
EU
GLE
Societe Generale
EU
CS
Axa
EU
BN
Danone
EU
BEL20
Bel 20
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
EU
ACA
Credit Agricole
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés